Cell adhesion is generally considered to depend on positive regulation through ligation of integrins and cytokine receptors. However, here we show that T-cell adhesion, and notably also T-cell receptor (TCR) -induced activation, are subject to constant suppression through shedding of low-density lipoprotein receptor-related protein 1 (LRP1). The broad-spectrum metalloprotease inhibitor GM6001 abrogated shedding, so inducing prominent cell surface expression of LRP1 while enhancing TCR-induced activation and adhesion to b 1 and b 2 integrin ligands, hence arresting the cells. Integrin ligands also inhibited shedding but the effect was less potent than that of GM6001. Unlike GM6001, integrin ligands also induced cell surface expression of full-length thrombospondin-1 (TSP170) and TSP130, which associated with LRP1, and TSP110, which did not associate with LRP1. Cell surface expression of LRP1 and TSP130 were induced exclusively in adhering cells, expression of TSP110 preferentially in non-adhering cells and expression of TSP170 correlated with T-cell motility. The pro-adhesive chemokine CXCL12 also inhibited LRP1 shedding and induced surface expression of TSP170 and TSP130 while inhibiting TSP110. Exogenous TSP-1 and ligation of CD28 inhibited shedding although less effectively than GM6001, and the inhibition through CD28 was independent of TSP-1. Small interfering RNA silencing experiments confirmed involvement of LRP1 and TSP-1 in integrin-dependent adhesion and TCR-induced activation. Hence, the poor LRP1 expression in T cells depends on shedding. Integrin ligands and CXCL12 antagonize shedding through a TSP-1-dependent pathway and ligation of CD28 antagonizes shedding independent of TSP-1. The disappearance of LRP1 from the cell surface may provide basic immunosuppression at the T-cell level.
Introduction
T lymphocytes have several unique properties that collaborate to promote adaptive immune responses, which defend the body against infectious agents and cancer but also unfortunately may cause autoimmune and allergic diseases. These properties include capacity to distinguish self from non-self, to reposition themselves between the vascular system and lymphoid and non-lymphoid organs combined with high motility. The T-cell antigen receptor (TCR) recognizes antigens as processed peptides presented in the context of self MHC molecules on antigenpresenting cells. Together with engagement of the TCR the co-stimulatory molecule CD28 is important for the generation of effective T-cell responses and immunological memory. An additional perhaps neglected unique property of T cells is that they contact multiple environmental tissue elements transiently but unlike most tissue cells do not adhere permanently. Hence, multiple integrin-mediated adhesive interactions with endothelial cells, antigen-presenting cells and components of the extracellular matrix play a pivotal role for T-cell extravasation, migration in tissues, antigen recognition, development of immunity or tolerance as well as immunological diseases. [1] [2] [3] [4] [5] [6] [7] Antigen recognition represents intriguing evidence for the concept that T cells respond to ª 2017 John Wiley & Sons Ltd, Immunology, 152, 308-327 environmental counter-receptors but prefer motility before attachment leading to arrest. The recognition of processed peptides in complex with MHC molecules therefore involves transient serial adhesive contacts between T cells and antigen-presenting cells and the cells maintain a significant motility level. 2, 4, 6 Additional proof for the concept that T cells basically are non-adherent is derived from observations that they exhibit a similar motile behaviour without stopping in type 1 collagen matrices, for which they lack adhesion receptors, and in Matrigel, which contains extracellular matrix components for which they have receptors. [8] [9] [10] Research to elucidate the mechanistic background of adhesion has focused on positive regulation. Hence, it is generally held that T-cell adhesion is controlled by chemokine-or antigen-induced up-regulation of the capacity of integrins to bind to counter-receptors on endothelial cells and antigen-presenting cells through inside-out and outside-in signalling. [11] [12] [13] However, in spite of the fundamental importance of adhesive interactions for T-cell function the mechanisms that control these interactions remain unclear.
14- 16 Here we show that T-cell adhesion through the major adhesion receptors b 1 and b 2 integrin, and TCR-induced activation, are suppressed through shedding of low-density lipoprotein receptor-related protein 1 (LRP1), a 600 000 member of the low-density lipoprotein receptor family that binds more than 30 distinct ligands, including the 450 000 matricellular protein thrombospondin-1 (TSP-1), and is involved in endocytosis and cell signalling. [17] [18] [19] [20] T cells produce TSP-1 that seems to be involved in integrin-dependent adhesion. 21 Platelets and endothelial cells have been reported to express full-length TSP-1 alone. 22 It is interesting in this context that healthy individuals have a 140 000 TSP-1 fragment in the circulation that is increased in patients with cancer, and that attempts to induce formation of this fragment in platelets in vitro failed. 22 We now show that T cells, unlike platelets and endothelial cells, contain full-length TSP-1 but in addition prominent 130 000 and 110 000 MW TSP-1 fragments. These preformed intracellular TSPs can be induced to appear on the cell surface through ligation of b 1 and b 2 integrins and CXCR4 that play pivotal roles for T-cell adhesion and extravasation and as co-stimulatory receptors for TCR-induced activation.
Materials and methods

Chemicals, antibodies and recombinant proteins
See Table 1 .
Cells
Human blood lymphocytes from healthy volunteers were purified using Lymphoprep and depleted of monocytes by treatment with carbonyl iron and magnetic removal of phagocytic cells. The use of lymphocytes from the blood of healthy individuals was approved by the local ethics committee. The cell preparations obtained consisted of 82-93% CD3-positive cells. Further enrichment of T cells was accomplished by depleting CD56-, CD19-and CD14-positive cells using beads coated with the corresponding antibodies. Lymphocytes were cultured in RPMI-1640 supplemented with 2 mM L-glutamine, 0Á16% sodium bicarbonate, 10 000 U/ml benzylpenicillin, 10 000 lg/ml streptomycin and 10% fetal calf serum or in serum-free AIM-V medium. The experiments were performed under serum-free conditions to exclude any interference of exogenous proteins and peptides.
Small interfering RNA-mediated gene silencing
The expression of LRP1 was suppressed using the human T-cell Nucleofector kit (Lonza, K€ oln, Germany) and a Nucleofector device (Amaxa biosystems, K€ oln, Germany) as previously described. Briefly, 5 9 10 6 T enriched cells were resuspended in 100 ll of nucleofactor solution and transfected with 500 nM final concentration of small interfering RNA (siRNA) using protocol U14. The siRNA consisted of TSP-1 siRNA (human) (Alternative 1) (A: Sense: CCACGAUGAUGACAACGAUtt. Antisense: AUCGUUGUCAUCAUCGUGGtt. B: Sense: CGAGACGAUUG UAUGAAGAtt. Antisense: UCUUCAUACAAUCGUCUC Gtt. C: Sense: GAAGAAGCGUAAAGACUAUtt. Antisense:AUAGUCUUUACGCUUCUUCtt), LRP1 siRNA (Alternative 1) (human). Sense: AAGACUUGCAGCCCC AAGCAGtt. Antisense: CUGCUUGGGGCUGCAAGUCUUtt) and control siRNA (sc-37007) from Santa Cruz Biotechnology (Dallas, TX) delivered by AH diagnostics, Sk€ arholmen, Sweden. TSP-1 siRNASuppl (human): (Sense: GCAUGACCCUCGUCACAUAtt. Antisense: UAUGUGACGAGGGUCAUGCca.) and LRP1 SiRNASuppl (human) (Sense: GCUGUGACAUGGACCAGUUtt. Antisense:AACUGGUCCAUGUCACAGCgg) were obtained from Applied Biosystems (Stockholm, Sweden). The degree of gene silencing and the influence of silencing on adhesion and activation were determined 40 hr after introducing siRNAs.
Quantitative immunocytochemistry
The expression of cell surface antigens was analysed in cells fixed in 2% paraformaldehyde at 4°attached to glass slides coated with poly-L-lysine (PLL), intercellular adhesion molecule 1 (ICAM-1) or fibronectin at 4°overnight. Antigen expression was detected with monoclonal antibodies and a complex of biotinylated peroxidase and avidin (Vector Laboratories, Burlingame, CA). For detection of intracellular antigens cells were fixed in 2% paraformaldehyde and permeabilized by 0Á1% saponin.
The cells were examined in a Nikon Eclipse E1000M microscope. The intensity of the immunocytochemical staining was quantified using the image processing and analysis program IMAGEJ.
Biotinylation and immunoprecipitation
The surface membrane of intact lymphocytes was labelled with D-biotinyl-e-aminocaproic acid-N-hydroxysuccinimide ester (biotin-7-NHS) as described by the manufacturer (Roche Diagnostics GmbH, Germany). For immunoprecipitation, adherent cells were biotinylated, released by a cell scraper and then immunoprecipitated. Cells in suspension and non-adherent cells were biotinylated and immunoprecipitated directly. The reaction was stopped with 75 ll stop solution per tube after incubation for 15 min at room temperature and centrifuged at 490 g for 10 min. The supernatant was discarded and 5 ml cold PBS was added to each tube followed by centrifugation at 490 g for 10 min. The cells were lysed in 1 ml lysis buffer (50 mM core buffer, 150 mM NaCl, 0Á1 mg/ml PMSF, 1 lg/ml aprotinin, 1 lg/ml leupeptin, 1% Nonidet P-40 and 0Á5% sodium deoxycholate) and incubated for 30 min on ice. After incubation for 15 min the cells were resuspended and centrifuged at 12 000 g for 10 min at 4°and the supernatants were transferred to clean Eppendorf tubes.
Immunoprecipitation was essentially carried out with protein G agarose beads as described by the manufacturer (Roche). The supernatants were mixed with 1 lg antibody at 4°overnight followed by centrifugation at 12 000 g at 4°for 20 seconds. Subsequently, the supernatants were discarded and the beads were resuspended in 1 ml washing buffer, and centrifuged again at 12 000 g at 4°for 20 seconds, the same procedure was repeated twice. After washing, 20 ll reducing buffer (29, containing 0Á15 g dithiothreitol in 5 ml immunoprecipitation buffer (150 mM NaCl, 10 mM Tris-HCL pH 7.4)) was mixed with the beads and heated at 95°for 4 min and subsequently centrifuged at 7000 g for 1 min to spin down the beads and the proteins were separated on SDS-PAGE gels. Proteins were transferred to the Hybond ECL membrane (Amersham, Chalfont St Giles, UK) and detected using the BMC chemiluminescence blotting kit (Roche). 
Western blotting
The samples were separated on SDS-PAGE gels and blotted onto a nitrocellulose membrane (Amersham), blocked over night with PBS, 4% BSA, and 0Á5% Tween. Filters were washed with PBS with 1Á5% BSA and incubated with antibodies. ECL Western blotting detection reagents were used for detection with Hyperfilm TM (Amersham).
Cell motility
Collagen type 1 was diluted in serum-free RPMI-1640 and H 2 O (8/1/1), applied in plastic Petri dishes 1 ml/dish (30 mm; BD Biosciences, Franklin Lakes, NJ) and allowed to polymerize at room temperature. A total of 1Á0 9 10 6 cells in AIM-V medium was added to each well with and without antibodies and allowed to migrate for different times. The cells were fixed in 2Á5% glutaraldehyde for 10 min or in 2% paraformaldehyde for 20 min for immunocytochemistry and washed twice with PBS. Cell morphology and cell migration were evaluated in nine fixed positions in each well and at 50-lm intervals throughout the gel by the use of an inverted microscope (Nikon Eclipse TE300) and a digital depth meter (Heidenheim ND221). The results are given as mean number of infiltrating cells/field (920 objective) per infiltration depth (50 lm for the first two layers immediately beneath the gel surface and 100 lm for other layers further down). The infiltrating cells were identified in situ in the collagen gels using immunocytochemistry after fixation in paraformaldehyde. Migration was also analysed in a modified Boyden assay (transwell assay) using 8-lm nucleopore filters coated with ICAM-1 (2 lg/ml) or fibronectin (10 lg/ml). The lower wells of 48-well Boyden chambers were filled with RPMI containing 1 mg/ml BSA and CXCL12 (50 ng/ml) whereupon the coated filters were placed in the chambers. The upper chambers were filled with 50 ll of 2 9 10 6 cells/ml in AIM-V. Following incubation for 1 hr the number of cells in the lower chamber was counted in triplicate.
Cell adhesion
To study cell adhesion, plastic Petri dishes (90 mm; Heger A/S, Rjukan, Norway) were coated with ICAM-1 (2 lg/ml), poly-L-lysine (10 lg/ml) or fibronectin (10 lg/ ml), and extensively washed before use. To analyse adhesion, the cells (10 000/position) in AIM-V medium were incubated on the substrates for different times, fixed in 2Á4% cold glutaraldehyde for 10 min or in 2% paraformaldehyde for 20 min for immunocytochemistry and unbound cells removed by gentle aspiration. The number of adherent cells per microscope field (209 objective) was counted.
T-cell activation
Mixed lymphocyte culture activation was accomplished by co-culture of T cells with inactivated allogeneic GM alone does not enhance TSP-1 expression in cells on PLL whereas GM markedly enhances TSP-1 expression in cells on fibronectin but has little effect on calreticulin expression. Interestingly, calreticulin seems to be distributed in spots on the cell surface whereas TSP-1 and LRP1 (a) show a confluent pattern of expression. It is also evident from the photographs that platelets express TSP-1 to the same extent in the absence of GM and that virtually all cells show enhanced cell surface expression of TSP-1. (c) Influence of permeabilization of the cells on the reactivity of antibodies to TSP-1 (Ab-4) and LRP1 (A2MRa-2). The reactivity of these antibodies with permeabilized cells was weak. However, permeabilized cells incubated with brefeldin A (10 lg/ml) to inhibit transport to the cell surface showed a mean intensity of 104 AE 39 with anti-TSP-1 (ab-4) and 108 AE 43 with anti-LRP1 (A2MRa-2) (not shown in figure) , whereas the mean intensity of non-permeabilized control cells incubated with brefeldin A was 11 AE 9 (anti-TSP-1) and 9 AE 7 (anti-LRP1). Non-permeabilized cells did not show reactivity with anti-actin antibodies, indicating that the fixation procedure did not expose intracellular antigens. stimulator cells whereupon interferon-c (IFN-c) and interleukin-2 (IL-2) production was determined by an Elispot assay. T-cell activation was also accomplished by culture of T cells on a surface coated with anti-CD3 antibodies with and without CXCL12.
ELISA
Ninety-six-well polystyrene plates were coated with 0Á25 lg/ well of RAP overnight in coating buffer (1Á59 g Na 2 CO 3 , 2Á93 g NaHCO 3 , 200 mg NaN 3 ) at 4°overnight and incubated with medium samples for 1 hr at 4°. Bound LRP1 was detected using anti-LRP1 antibody 0Á001 lg/ml (1 hr; 4°), rabbit anti-mouse diluted 1:1000 (1 hr; 4°), and a sheep anti-rabbit immunoglobulin diluted 1 : 4000 (1 hr; 4°).
Statistical analysis
Staining intensity in immunocytochemistry experiments, number of migrating cells and adherent cells are presented as mean arbitrary units AE SD and the MannWhitney U-test was used to evaluate differences between groups. For determination of differences in migration assays paired Student's t-test was used. Two-tailed Pvalues < 0Á05 were considered statistically significant.
Results
The control of cell surface-expressed LRP1 and TSP-1 in T cells
To investigate the possible influence of proteases on the cell surface expression of LRP1 we incubated primary T cells and T cells activated by anti-CD3 (50 ng/ml), IL-2 (10 ng/ ml) and IL-4 (20 ng/ml) in the presence of the broad-spectrum metalloprotease (MMP) inhibitor GM6001 (also called Galardin and Ilomastat) (10 lM), the granzyme A inhibitor PPACK (10 lM), the granzyme B inhibitor Ac-IETD-CHO (50 lM) and the uPA inhibitor amiloride (0Á2 mM). The experiments were performed in serum-free medium to exclude any interference of exogenous proteins and peptides. This choice of inhibitors was based on the fact that T cells express granzyme A and B, the receptor for uPA, uPAR, as well as MMPs. Given our previous finding that the surface expression of LRP1 and TSP-1 on T cells is increased by contact with fibronectin or ICAM-1 23 we also combined incubation of cells on these integrin ligands with exposure to protease inhibitors. The cell surface expression of TSP-1, calreticulin and CD4 was studied as controls. As an additional control we compared the influence of protease inhibitors and integrin ligands on platelet expression of TSP-1 and LRP1. Figure 1 shows the reactivity of antibodies to LRP1, TSP-1 and calreticulin in T cells adhering to ICAM-1 (2 lg/ml), fibronectin (10 lg/ml) and PLL (10 lg/ml) -coated surfaces. It is evident from the photographs in Fig. 1 (a-c) and from the quantification of staining intensity in Fig. 1 (d) that cells attached to PLL in the absence of protease inhibitors expressed negligible surface expression of LRP1 and TSP-1 in comparison with cells on ICAM-1 and fibronectin (P < 0Á01). It is also evident from Fig. 1 (a) and from quantification of staining intensity (Fig. 1d,e ) that the presence of GM6001 caused a markedly increased surface expression of LRP1 in almost all cells on fibronectin, ICAM-1 and PLL within 5 min. This increase was seen in both non-stimulated and activated cells. Inhibitors of granzymes or uPA did not affect LRP1 expression (Fig. 1d ). GM6001 did not increase the cell surface expression of calreticulin and CD4 (Fig. 1b,  d ). GM6001 did not affect the cell surface expression of TSP-1 in cells on PLL. In contrast, contact with ICAM-1 and fibronectin increased the cell surface expression of TSP-1 and the incubation of cells on fibronectin and ICAM-1 in the presence of GM6001 further enhanced TSP-1 expression (Fig. 1b,d ). Contact with fibronectin and ICAM-1 also enhanced LRP1 expression whereas contact with PLL did not. The enhancement of LRP1 expression by contact with fibronectin and ICAM-1 was less potent than that of incubation in the presence of GM6001. Permeabilized cells incubated on PLL without GM6001 exhibited relatively little TSP-1 and almost negligible expression of LRP1 (Fig. 1c) in comparison with the surface expression of TSP-1 and LRP1 in cells incubated with GM6001 (LRP1) or on ICAM-1 and fibronectin in the presence of GM6001 (TSP-1 and LRP1) (Fig. 1a,b) . This weak intracellular TSP-1 and poor LRP1 expression are consistent with our previous findings that the protein transport inhibitor brefeldin A inhibits their surface expression ( Fig. 1c and legend) while increasing the intracellular expression and therefore is useful to detect silencing of these molecules. 24, 25 Anti-TSP-1 antibodies showed strong reactivity to platelets whereas anti-LRP1 antibodies lacked reactivity. This means that these antibodies identify different antigens and probably excludes the possibility that cross-reactivity influences the present experimental results. In conclusion, the influence of GM6001 shown in Fig. 1 indicates that inhibition of MMPs causes a potent increase of the cell surface expression of LRP1. Integrin ligands induce both TSP-1 and LRP1 expression although they are weaker stimulators of LRP1 expression than GM6001.
The lack of surface expression of TSP-1 and LRP1 in cells attached to PLL shows that the fixation or the staining procedure does not expose intracellular antigens (Fig. 1c) . The viability of cells incubated with GM6001 and the other inhibitors was virtually identical to that of control cells, which strongly argues against the possibility that toxic effects played any role for the results (see legend to Fig. 1d ).
Preformed TSP-1 fragments induced to appear on the cell surface Gel analysis of immunoprecipitated material from surface-biotinylated cells was performed to investigate the influence of GM6001 and contact with integrin ligands on the surface expression of LRP1 and TSP-1 (Fig. 2a ). An antibody to LRP1 lacked reactivity to control cells incubated without GM6001 or contact with ICAM-1, whereas an antibody to TSP-1 precipitated a barely visible 170 000 MW band (Fig. 2a lane 1 ) that corresponds to full-length TSP-1. In cells incubated in the presence of GM6001, anti-LRP1 precipitated a 500 000 MW band, which corresponds to LRP1, a weak 170 000 band and a suggestive 130 000 band. In cells incubated in the presence of GM6001, anti-TSP-1 precipitated a 170 000 band and an almost negligible 500 000 band. In cells on ICAM-1, anti-LRP1 precipitated a prominent 500 000 band and relatively weak 170 000 and 130 000 bands. In cells on ICAM-1, anti-TSP-1 precipitated a weak 500 000 In cells incubated on ICAM-1 in the presence of GM6001, anti-LRP1 precipitated a very prominent 500 000 band and prominent 170 000 and 130 000 bands, whereas anti-TSP-1 precipitated very prominent 170 000 and 130 000 bands and a prominent 500 000 band. Hence, anti-LRP1 consistently precipitated a relatively stronger 500 000 band, whereas anti-TSP-1 precipitated relatively stronger 170 000 and 130 000 bands. ICAM-1 and GM6001 had a synergistic stimulatory effect on the bands identified using anti-LRP1 and anti-TSP-1 antibodies. Control IgG and anti-CD4 did not precipitate any high molecular weight bands, strongly indicating that the bands precipitated using anti-LRP1 and anti-TSP-1 antibodies are specific and this conclusion is further corroborated by their differential reactivity to platelets. Western blotting of cells incubated on ICAM-1 in the presence of GM6001 confirmed that the 500 000 band is LRP1 and that the 170 000 and 130 000 bands are TSP-1 (Fig. 2b) . This Western blot also confirmed that anti-LRP1 co-precipitated TSP170 and TSP130, whereas anti-TSP-1 co-precipitated LRP1. The reactivity of the anti-LRP1 and anti-TSP-1 antibodies in Fig. 2(a,b) also verified the results in Fig. 1 that the presence of GM6001 preferentially stimulates LRP1 expression, whereas ICAM-1 stimulates both LRP1 and TSP-1 expression. The results in Fig 2(a,b) further indicate that TSP170 and TSP130 associates with LRP1 on the cell surface. The gel analysis in Fig. 2(c,d) compares the cell surface expression of TSP-1 induced by adhesion (Fig. 2c) with the total cellular TSP-1 before adhesion using Western blotting (Fig. 2d) . T cells before adhesion exhibited negligible surface expression of TSP-1 in agreement with the results in Fig. 2(a) . Adhesion to ICAM-1, triggered surface expression of 170 000 and 130 000 bands precipitated with an antibody to TSP-1. TSP130 appeared exclusively on adhering cells and was present in all experiments. TSP110 appeared as a prominent major band on non-adhering cells and as a relatively weak band in adhering cells where it was absent in several experiments. TSP170 appeared on both adhering and non-adhering cells. Western blotting of lysed cells before adhesion, which lacked surface TSP-1 as demonstrated in Fig. 2(c) , detected full-length 170 000 TSP-1, as well as 130 000 and 110 000 TSP-1 proteins ( Fig. 2d; see lane 1 -CXCL12 ). This means that these proteins were present intracellularly and were induced to appear on the surface by contact with fibronectin and ICAM-1. It is of great interest in this context to examine the influence of the CXCR4-and CXCR7-binding chemokine CXCL12 on TSP-1 expression because CXCL12 stimulates both T-cell adhesion and motility. As a control for CXCL12 we used the MMP inhibitor tissue inhibitor of metalloproteinase 1 (TIMP-1). TIMP-1 has a molecular weight of 28 000 which means that it, like CXCL12, does not enter cells. The Western blots in Fig. 2(d) show that CXCL12 (50 ng/ml), but not TIMP-1 (100 ng/ml), induced a significantly elevated total cellular expression of TSP170 accompanied by disappearance of TSP110. In the absence of stimuli that promote surface expression of LRP1 that could capture TSP-1 (Figs 1 and 2c) , the lack of effect of TIMP-1 on TSP-1 expression is logical. The lack of effect anti-lg + anti-CD28
anti-CD3 + anti CD- of TIMP-1 on TSP-1 expression further shows that the stimulatory effect of CXCL12 is specific. In addition to the influence of CXCL12 on the total expression of TSP-1 as shown by Western blotting (Fig. 2d ) its possible influence on the cell surface expression of TSP-1 was examined by immunoprecipitation of surface-biotinylated cells. We also compared the influence of CXCL12 with the influence of IL-2, which has been shown to stimulate T-cell motility and TSP-1 synthesis. 24 CXCL12 (50 ng/ml) was found to induce surface expression of TSP170 and TSP130, whereas IL-2 (10 ng/ml) induced surface expression selectively of TSP170 (Fig. 2e) . This implies that CXCL12 has an effect on the cell surface expression of TSP-1, which is coupled to its effect on the total expression of TSP-1, as shown in Fig. 2(d) .
We next compared the influence of exogenous TSP-1 (5 lg/ml) on the cell surface expression of LRP1 and TSP-1 in adherent cells and cells not allowed to adhere. It is evident from Fig. 2(f) that anti-LRP1 and anti-TSP-1 did not precipitate any significant bands in non-adherent cells, with and without exogenous TSP-1 in the medium. In contrast, in adherent cells, anti-LRP1 precipitated a prominent LRP1 band and barely visible TSP170 and TSP130 bands, whereas anti-TSP-1 precipitated strong TSP-1 bands and a strong LRP1 band. However, the anti-TSP1-precipitated LRP1 band was weaker than the LRP1 band precipitated with anti-LRP1. It is also evident from the prominent upper band in lane 4 that TSP-1 enhanced LRP1 expression. The results in Fig. 2(f) support the conclusion that LRP1 and TSP-1 are associated on the cell surface (Fig. 2a,b) and indicate that TSP-1 enhances LRP1 expression in adherent cells.
Figure 2(g) shows that inhibitors of granzyme B and uPA did not affect the pattern of expression of TSP170 and TSP130 on cells. In contrast, the C-terminal globular end peptide fragment of TSP-1, 4N1K (50 lM), prevented expression of TSP130. 4N1K was originally thought to target the integrin-associated protein CD47 26 but has later been shown to lack specificity. 27 4N1K has functional effects in T cells that differ from multiple control peptides by stimulating motility while inhibiting adhesion. 21, 25 In the light of the fact that 4N1K inhibited the expression of TSP130 it is interesting that 4N1K has significant antimicrobial activity, 28 which has generally been attributed to inhibition of protein synthesis. 29 The fact that an inhibitor of adhesion and stimulator of motility prevented appearance of the adhesion-associated TSP130, while being permissive for TSP170, indicates that TSP130 stimulates adhesion whereas TSP170 stimulates motility.
Ligation of integrins and CD28 antagonize shedding of LRP1
ADAM10 and its close homologue ADAM17 are sheddases that might be responsible for the results in Figs 1 and 2 as they are expressed in T cells, 30 cause shedding of LRP1 in non-lymphoid cells, and represent a general shedding machinery for membrane proteins. [31] [32] [33] Figure 3(a) shows that LRP1 was detectable in the culture medium of T cells and that GM6001 (10 lM) and the ADAM10 inhibitor GI254023X (5 lM) reduced the appearance of LRP1 in the medium. Inhibitors of granzymes and uPA did not inhibit the appearance of LRP1 in the medium. GI252023X also increased the cell surface expression of LRP1 (Fig. 3b) .
Media from cells on fibronectin and ICAM-1 contained significantly less LRP1 than media from cells on PLL (Fig. 3c) . Media from cells on fibronectin and ICAM-1, which induce cell surface expression of TSP-1, showed presence of TSP-1. This may reflect that the enhanced cell surface expression of TSP-1 is accompanied by enhanced TSP-1 secretion. The results in Fig. 3(c) together with those in Figs 1 and 2 indicate that integrin ligation inhibits shedding of LRP1. CXCL12 (50 ng/ml) was also Adherent cells/field found to reduce LRP1 shedding and CXCL12 and integrin ligands had a synergistic inhibitory effect on shedding (Fig. 3d) . We have previously presented evidence that TSP-1 induces cell surface expression of LRP1. 34 To investigate the possibility that TSP-1 inhibits shedding of LRP1, T cells were incubated in the presence of exogenous TSP-1. This TSP-1, but not IgG, was indeed found to prevent shedding of LRP1 (Fig. 3e) .
We next examined whether the enhancing effect of ligation of CD28 (anti-mouse IgG, 2 lg/ml + anti-CD28, 50 ng/ml) on LRP1 expression 35 was dependent on shedding. This experiment showed that CD28 ligation inhibited the appearance of LRP1 in the medium and increased cell surface LRP1 whereas CD3 ligation (antimouse IgG, 2 lg/ml + anti-CD3, 50 ng/ml) did not (Fig. 3f) . This is an important distinction as coating with anti-CD3 stimulated LRP1 expression in a T-cell clone. 21 However, this clone was repeatedly stimulated with antigen and it is therefore likely that the antigen-presenting cells used may have delivered a stimulus to CD28 that enhanced LRP1 expression. We conclude that ligation of CD28 inhibits shedding of LRP1 independent of TSP-1.
An anti-adhesive mechanism targeting LRP1
To investigate the influence of shedding of LRP1 on integrin-dependent adhesion, cells were allowed to settle on fibronectin and ICAM-1 in the presence and absence of protease inhibitors. The photographs in Fig. 1 and counting of adherent cells showed that GM6001 and GI252023X increased adhesion to fibronectin and ICAM-1 significantly in comparison with control cells and cells incubated with granzyme inhibitors (Fig. 4a-c) . The stimulatory effect of GM6001 could be inhibited by antibodies to b 1 and b 2 integrins (Fig. 4d,e) . Cells adhering to fibronectin and ICAM-1 in the presence of GM6001 and GI252023X were spherical (diameter ratio 1Á0) (Fig. 4f,g) whereas control cells and cells incubated in the presence of inhibitors of granzymes had a polarized morphology (diameter ratio 2-2Á5). This indicates that presence of GM6001 and GI252023X inhibited the motility of adherent cells.
To elucidate whether the stimulation of T-cell adhesion to fibronectin and ICAM-1 in the presence of GM6001 and GI252023X was dependent on LRP1 and/ or TSP-1 these molecules were silenced using siRNA (Figs 4h-j and 5a,b) . Scrambled control siRNA did not affect the number of cells adhering to fibronectin and ICAM-1 or the pattern of adhesion in the presence or absence of GM6001. TSP-1 siRNA inhibited the background adhesion as well as the stimulation of adhesion by GM6001. LRP1 siRNA enhanced adhesion which may seem inconsistent with a supporting role in adhesion (as shown in Fig. 7 , LRP1 siRNA as well as TSP-1 siRNA markedly reduced TCR-induced T-cell activation). However, LRP1 siRNA increased the cell surface expression of TSP-1 from 12 AE 6 to 41 AE 19 arbitrary units (Fig. 5b) consistent with previous findings. 25 Together with the evidence using TSP siRNA that adhesion is TSP-1-dependent this indicates that an increased cell surface expression of TSP-1 accounts for the enhancement of adhesion by LRP1 siRNA. TSP-1 siRNA did not affect adhesion to PLL, which most likely means that its inhibitory effect on adhesion to fibronectin and ICAM-1 was specific. The validity of the siRNA silencing results was supported by the fact that separate TSP-1 and LRP1 siRNAs had the same effect (Fig. 5a,b) as the siRNAs used in the primary experiments (silencing data shown; adhesion data not shown). This argues against the possibility that off-target effects were responsible for the results. These siRNA results together with the evidence that LRP1 and TSP-1 associate on T cells (Fig. 2) indicate that TSP-1 mediates LRP1-dependent adhesion to ICAM-1 and fibronectin. . Cells were allowed to adhere for 30 min with and without antibodies in the medium. It is evident that an anti-CD29 antibody inhibits GM-dependent adhesion to fibronectin and that an anti-CD18 antibody inhibits GM-dependent adhesion to ICAM-1. (f, g) Inhibitors MMPs and ADAMs inhibit development of a polarized cell shape on fibronectin (f) and ICAM-1 (g). The cells were incubated on fibronectin and ICAM-1 for 30 min in the presence and absence of Ac-IETD, PPACK, GM and GI and the degree of polarization was determined. The degree of polarization was significantly lower in the presence of GM and GI than in controls or with granzyme inhibitors. (h-j) Silencing of low-density lipoprotein receptor-related protein 1 (LRP1) and thrombospondin 1 (TSP-1) differentially affects adhesion to fibronectin and ICAM-1. The cells were transfected with scrambled control small interfering RNA (siRNA), LRP siRNA, TSP-1 siRNA or both LRP siRNA and TSP-1 siRNA and subsequently allowed to adhere to fibronectin (h), ICAM-1 (i) and poly-L-lysine (PLL) (j). It is evident that TSP1 siRNA but not LRP1 siRNA inhibited adhesion to fibronectin and ICAM-1 and the stimulatory effect of GM on adhesion. Data in ( Inhibition of the adhesion-inhibitory protease arrests adherent cells but not motility per se
The finding that GM6001 stimulated adhesion (Fig. 4) , while inducing a spherical morphology (Figs 1a and 4f,g ), suggested an effect on T-cell motility. To elucidate the possible role of proteases for motility, the cells were allowed to migrate into a collagen matrix, an established model for analysis of motility, 8, 10 in the presence and absence of protease inhibitors. This adhesion-independent motility model revealed no significant inhibitory effects of GM6001 and GI252023X (Fig. 6a) but rather an increased number of cells in the deeper layers of the collagen.
The influence of GM6001 and GI252023X on the motility of T cells adherent to fibronectin (10 lg/ml) and ICAM-1 (2 lg/ml) was also analysed in transwell experiments using CXCL12 (50 ng/ml) as attractant. Presence of GM6001 and GI252023X abrogated T-cell migration on ICAM-1 and fibronectin towards CXCL12 (50 ng/ml) in the lower well whereas a granzyme inhibitor did not inhibit motility (Fig. 6a,b) . Taken together the results in Fig. 6(a,b) probably mean that presence of the MMP/ ADAM inhibitors do not affect T-cell motility per se but have an indirect inhibitory effect on motility through enhancement of adhesion.
GM6001 and CXCL12 enhance TCR-induced T-cell activation through TSP-1 and LRP1
Others have demonstrated that GM6001 causes enhancement of allograft survival and the production of multiple cytokines.
36 GM6001 reduced cell infiltration in the allografts suggesting that the enhanced allograft survival is coupled to effects on cell motility or adhesion. The authors conclude that MMP/ADAM enzymatic activity plays a critical role in the pathogenesis of allograft rejection. We took advantage of this experimental approach in an attempt to investigate the possible influence of silencing of TSP-1 and LRP1 on GM6001-induced enhancement of cytokine production (Fig. 7a,b) . The transfected cells were activated by allogeneic cells and IFN-c and IL-2 production was determined by Elispot assays. It can be seen that GM6001 enhanced IFN-c and IL-2 production in control cells as well as in cells transfected with scrambled control siRNA with the report by Eaton et al. It is noteworthy that the enhancing effect of GM6001 on IFNc and IL-2 production was significantly reduced in TSP-1 siRNA and LRP siRNA transfected cells. However, the most powerful inhibitory effect on GM6001-induced IFN-c and IL-2 production was observed in cells transfected with both TSP-1 siRNA and LRP1 siRNA. TSP siRNA and LRP1 siRNA also inhibited MLC-induced cytokine production. These effects of silencing indicate that TSP-1 and LRP1 support cytokine production and that GM6001 enhances T-cell activation through TSP-1 and LRP1.
The evidence that the co-stimulatory chemokine CXCL12 inhibited shedding of LRP1 and directed the formation of TSP-1 fragments (Figs 3d and 2d,e) suggested that CXCL12 induces co-stimulation through TSP-1 and LRP1. We therefore examined the influence of knockdown of TSP-1 and LRP1 on T-cell activation by anti-CD3 (50 ng/ml) in the presence of CXCL12 (Fig. 7c) . TSP-1 siRNA was found to inhibit anti-CD3-induced IFN-c production as well as the enhancing effect of CXCL12. Control siRNA did not inhibit IFN-c production. LRP1 siRNA had a relatively weak albeit significant inhibitory effect whereas a combination of TSP-1 siRNA and LRP siRNA had a pronounced inhibitory effect. 
Discussion
These results show that the poor LRP1 expression in T cells may be accounted for by disappearance from the cell surface through shedding. T cells therefore have a prominent cell surface expression of LRP1 if shedding is prevented. This negative regulation of LRP1 expression is coupled to suppression of T-cell adhesion to fibronectin and ICAM-1 and to suppression of TCR-induced activation. The mechanistic implications of these findings are described in Fig. 8 .
As shown by the fact that permeabilized cells exhibited weak reactivity with an anti-LRP1 antibody, LRP1 is present in relatively small amounts intracellularly and probably destined for direct transport to the plasma membrane where it is cleaved off. Shedding of LRP1 seems to be dependent on ADAM10 consistent with previous findings that ADAM10 is expressed in T cells and causes shedding of LRP1 in non-lymphoid cells 28, 31 but further studies are needed to elucidate this. The pronounced spontaneous LRP1 shedding in T cells is unique as shedding of various components, including LRP1, in other cell types is a response to exogenous stimulation. [31] [32] [33] Shedding is inhibited by exogenous TSP-1, which taken together with the fact that adhesion correlates with surface expression of LRP1 and endogenous TSP130 indicates that TSP-1 regulates integrin-induced responses in collaboration with LRP1. Shedding of LRP1 is also inhibited through ligation of CD28 but unlike ligation of integrins or CXCR4, ligation of CD28 inhibits LRP1 shedding independent of TSP-1. It is intriguing that CXCL12, b 1 and b 2 integrin ligands, and ligation of CD28, all of which play pivotal roles in the behaviour, fate and function of T cells, and provide co-stimulation, mimicked MMP/ADAM inhibitor-induced inhibition of shedding and enhancement of adhesion. This suggests that upregulated cell surface expression of LRP1 through inhibition of shedding is a principal pro-adhesive and costimulatory pathway. LRP1 is a regulator of cell survival, 37 which is interesting in the light of its up-regulation by CD28 ligation, as CD28 co-stimulation stimulates survival. 38 It is also interesting that the glucose transporter GLUT4 has been shown to be associated with LRP1 in non-lymphoid cells and glucose transport has been demonstrated to be a target for CD28 ligation. 39, 40 Shedding of LRP1 inhibits permanent b 1 and b 2 integrin-dependent T-cell adhesion and arrest favouring transient environmental contacts and motility. Therefore, the disappearance of LRP1 from the cell surface probably favours the hunt for the cognate antigen by the relatively few cells specific for each antigen and may contribute significantly to maintain T-cell surveillance of the organism. The disappearance of LRP1 may also have an important physiological function by limiting lymphocyte adhesion to endothelial and epithelial cells or extracellular matrix components and consequently accumulation at sites of inflammation. The inhibition of adhesion and the antagonistic effect on T-cell activation indicates that shedding of LRP1 constitutes an immunosuppressive mechanism, which may prevent adverse T-cell activation, maintain tolerance to self-antigens and protect against autoimmunity and allergy. The present findings therefore suggest a novel mechanism for inhibition of adaptive immune responses in addition to the immune checkpoint proteins cytotoxic T lymphocyte antigen-4 and programmed death-1 and regulatory T cells.
The present study shows that T cells have 130 000 and 110 000 TSP-1 fragments, whereas others have demonstrated that platelets and endothelial cells merely express full-length TSP-1. 22 This probably excludes the TSP-1 fragments detected in the present study being derived from platelets, which often contaminate purified T cells. Healthy individuals have a 140 000 TSP-1 fragment in circulation, which is increased in cancer patients. 22 The 
Control
Control+siRNA TSP siRNA LRPsiRNA TSPsiRNA+ LRPsiRNA failure to induce formation of the 140 000 TSP-1 fragment in platelets 22 points to the possibility that this fragment represents T-cell-derived TSP130.
Adhesion to b 1 and b 2 integrin ligands induced cell surface expression of preformed intracellular TSP170, TSP130 and TSP110. It is intriguing that TSP130 appeared exclusively on adhering cells whereas TSP110 appeared preferentially on non-adhering cells. Cell surface-expressed TSP170 and TSP130, but not TSP110, associated with LRP1 and correlated with inhibition of shedding, suggesting that they inhibit the sheddase responsible. Its association with LRP1 and its presence exclusively on adherent cells indicate that TSP130 has a pro-adhesive effect. However, an alternative interpretation is that integrin ligation inhibits the sheddase responsible for cleavage of LRP1 leading to a selective binding of TSP130 to LRP1. TSP170 is probably motogenic, as shown by the fact that the motogenic factors IL-2 and 4N1K stimulated surface expression of TSP170. Cell surface expression of TSP110 was coupled to a distinct integrin-induced response that neither inhibited shedding nor promoted adhesion and may represent a state of inertness vis-a-vis adhesion. The b 1 and b 2 integrin-dependent surface expression of TSP170 and TSP110 in non-adhering cells shows that even transient integrin contacts can elicit a T-cell response. Such abortive adhesion responses may be functionally important by preventing adhesive interactions and T-cell activation. In light of the fact that TSP170 seems to be motogenic and counteradhesive, we propose that basal cell surface expression in favour of TSP170 before the 'pro-adhesive' TSP130 accounts for the fact that T cells only adhere transiently. Our results suggest that preformed TSP fragments in collaboration with LRP1 determine the behaviour and fate of T cells with respect to adhesive contacts with endothelial cells, extracellular matrix components and antigen-presenting cells.
The differential expression of TSP170, TSP130 and TSP110 may account for the type of functional responses induced by different cytokines and may have bearing on the understanding of autoimmune inflammatory diseases and their treatment. For example CXCL12, which is both motogenic and pro-adhesive, was found to direct the TSP-1 repertoire in favour of TSP170 and TSP130, while suppressing TSP110, whereas the primarily motogenic IL-2 was found to direct the surface expression of this repertoire in favour of TSP170. It is interesting in this context that CXCL12 and particularly IL-2 have established preventive effects against autoimmune diseases. [41] [42] [43] [44] The stimulatory effect of IL-2 on the expression of TSP170 suggests that the motogenic effect of TSP170 is immunosuppressive. In support of this interpretation, the cornerstone therapy for many autoimmune diseases, methotrexate, stimulates surface expression of TSP170 and motility in T cells. 45 Hence, methotrexate mimics IL-2 and partly CXCL12 with respect to stimulation of expression of TSP170, suggesting that full-length TSP-1 inhibits T-cell activation through its motogenic effect and therefore can dampen inflammatory diseases. This suggests that the immunosuppressive LRP1 mechanism for T-cell regulation, besides the disappearance of LRP1, is endowed with an additional immunosuppressive element in TSP170.
The results of silencing of TSP-1 and LRP1 indicate that TCR-induced T-cell activation depends on both LRP1 and TSP-1, probably through signalling via LRP1. The results of silencing of TSP-1 and LRP1, together with the fact that the cell surface expression of LRP1 correlates with adhesion, indicate that b 1 and b 2 integrin ligands, in collaboration with CXCL12, induce adhesion primarily through TSP130 associated with LRP1. The fact that LRP1 knockdown did not inhibit adhesion may seem to argue against the possibility that adhesion depends on outside-in signalling via LRP1 and rather to suggest that TSP-1 promotes adhesion independent of LRP1. However, the enhanced adhesion by LRP1 knockdown, which probably reflects enhanced cell surface expression of TSP-1, may also be interpreted as evidence for an important balancing role of LRP1 in adhesion. Accordingly, disappearance of a key element, such as LRP1, in a large interactome may cause extreme adhesion because its motogenic effect disappears. 23, 24 The possibility that TSP-1 may promote integrin-dependent adhesion via binding to b 1 integrins in cis, for which TSP-1 has binding sites, 46, 47 seems less likely because the same region within TSP-1 binds to both integrins and LRP1. However, as previously proposed the LRP/TSP-1 complex may enhance b 1 and b 2 integrin-dependent adhesion through CD47 in cis for which TSP-1 has a binding site. 21, 48 The present findings have far-reaching implications for understanding immune responses and their regulation as well as previous findings in the literature. This applies to the influence of CXCL12 and IL-2 on motility and adhesion as discussed above. The LRP1/TSP-1-driven immunoregulatory mechanism may also account for seemingly contradictory findings that MMP/ADAM inhibitors on the one hand prevent allograft rejection while on the other hand they enhance activation of alloreactive T cells. 36 Our findings may explain this paradox by predicting that MMP/ADAM inhibitors would enhance activation as well as adhesion in lymphoid organs or at the endothelium of target organs, hence arresting the cells and preventing infiltration and rejection. Our findings also provide an alternative explanation for the conclusion that ADAMs are required for transendothelial migration of leucocytes, based on studies showing that MMP/ ADAM inhibitors arrest cells at the endothelium. ICAM-1 was found to be enriched around transmigrating leucocytes and continued to surround the cells during transmigration. 49, 50 The present results make it reasonable to assume that MMP/ADAM inhibitors, which are permissive for motility per se, inhibit transmigration by enhancing adhesion to endothelial ICAM-1. Enhanced adhesion through inhibition of LRP1 shedding may also explain why T cells under some circumstances may be stationary within tissue niches. 51 Our findings further point to the possibility that shedding of LRP1 may serve to prevent adverse activating signals on the immune system by LRP1-binding factors, such as heat-shock proteins, shown to bind to LRP1 in non-lymphoid cells. 52 In conclusion, the present findings indicate that T cells are subject to constant functional suppression through disappearance of LRP1 from the cell surface. This suppression seems particularly important because of its potency, which is fully unveiled by inhibition at the protease level. In contrast, inhibition of the disappearance of LRP1 from the cell surface through ligation of integrins, CXCR4 and CD28 is less effective. A reasonable explanation why these immunostimulatory pathways are less effective may be that immunosuppression has higher priority.
